MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$7.98−0.16 (-1.97%)
Close on Nov 20, 2026Market cap $766.42MP/E 11.2Yield –
MeiraGTx free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
MeiraGTx's free cash flow for the twelve months ending Jun 30, 2026 was $10.47M. For fiscal 2025 it was -$50.19M. The highest annual figure on record is $11.06M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$50.19M | – |
| FY2024 | Dec 31, 2024 | -$109.45M | – |
| FY2023 | Dec 31, 2023 | -$125.54M | – |
| FY2022 | Dec 31, 2022 | -$118.06M | – |
| FY2021 | Dec 31, 2021 | -$56.88M | – |
| FY2020 | Dec 31, 2020 | -$84.89M | -867.2% |
| FY2019 | Dec 31, 2019 | $11.06M | – |
| FY2018 | Dec 31, 2018 | -$70.15M | – |
| FY2017 | Dec 31, 2017 | -$28.59M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$38.87M | – |
| Q1 FY2026 | Mar 31, 2026 | $15.80M | – |
| Q4 FY2025 | Dec 31, 2025 | $46.36M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.83M | – |
| Q2 FY2025 | Jun 30, 2025 | -$45.18M | – |
| Q1 FY2025 | Mar 31, 2025 | -$38.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.75M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.42M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$33.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$46.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.76M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.74M | – |
| Q2 FY2022 | Jun 30, 2022 | -$41.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.76M | -552.8% |
| Q4 FY2021 | Dec 31, 2021 | -$5.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$29.09M | – |
| Q2 FY2021 | Jun 30, 2021 | -$26.84M | – |
| Q1 FY2021 | Mar 31, 2021 | $4.58M | – |
| Q4 FY2020 | Dec 31, 2020 | -$37.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.42M | -120.3% |
| Q4 FY2019 | Dec 31, 2019 | -$26.72M | – |
| Q3 FY2019 | Sep 30, 2019 | -$20.43M | – |
| Q2 FY2019 | Jun 30, 2019 | -$22.84M | – |
| Q1 FY2019 | Mar 31, 2019 | $81.05M | – |
| Q4 FY2018 | Dec 31, 2018 | -$20.35M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.05M | – |
| Q2 FY2018 | Jun 30, 2018 | -$19.14M | – |
| Q1 FY2018 | Mar 31, 2018 | -$18.61M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.86M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.38M | – |
See a number that looks wrong?